Baxter International, Inc. Names Chief Financial Officers For New Biopharmaceutical Spin-Off And Baxter International Inc.

free biotech news Get the latest biotech news where you want it. Sign up for the 

free GenePool newsletter today!

Baxter International Inc. (NYSE:BAX) announced that upon completion of the tax-free distribution of the company’s biopharmaceuticals business, Robert J. Hombach, currently chief financial officer for Baxter International Inc., will be appointed chief financial officer and will assume additional operational responsibilities for the independent biopharmaceuticals company. Hombach will report to Ludwig N. Hantson, PhD., who will serve as the new company’s CEO. James K. Saccaro will rejoin Baxter August 4, 2014, and will assume the role of chief financial officer of Baxter International Inc., reporting to Robert L. Parkinson, Jr., Baxter’s chairman and CEO, following completion of the transaction in 2015.

Help employers find you! Check out all the jobs and post your resume.

Back to news